Our strategy consists of an HAdV5 vector carrying a proapoptotic gene PUMA, complexed on recombinant baculovirus (BV) displaying CAR on the baculoviral envelope (BVCAR)14. The BVCARHAdV5-PUMA complex exploits the capacity of the BVs to enter FLSs, resulting in efficient HAdV5 transduction of FLS in vitro and in vivo. Both the HAdV5 and BVs are non-integrative vectors and are considered biologically safe. BVs have a biosafety profile due to their incapacity to replicate in mammalian cells17, 18.